Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Genmab A/S ADR
(NQ:
GMAB
)
28.20
+0.21 (+0.75%)
Official Closing Price
Updated: 4:15 PM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
479,399
Open
28.13
Bid (Size)
28.21 (23)
Ask (Size)
28.23 (7)
Prev. Close
27.99
Today's Range
27.98 - 28.42
52wk Range
26.32 - 42.72
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
June 01, 2024
From
Genmab A/S
Via
Business Wire
Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session
May 24, 2024
Via
Benzinga
Performance
YTD
-12.18%
-12.18%
1 Month
-0.95%
-0.95%
3 Month
-3.29%
-3.29%
6 Month
-10.82%
-10.82%
1 Year
-30.42%
-30.42%
More News
Read More
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
Genmab A/S
Via
Business Wire
What 9 Analyst Ratings Have To Say About Genmab
May 20, 2024
Via
Benzinga
NASDAQ:GMAB is showing good growth, while it is not too expensive.
May 02, 2024
Via
Chartmill
Genmab Completes Acquisition of ProfoundBio
May 21, 2024
From
Genmab A/S
Via
Business Wire
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
May 20, 2024
Via
InvestorPlace
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
May 14, 2024
From
Genmab A/S
Via
Business Wire
GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
Via
InvestorPlace
Decoding 9 Analyst Evaluations For Genmab
April 30, 2024
Via
Benzinga
NASDAQ:GMAB is not too expensive for the growth it is showing.
April 11, 2024
Via
Chartmill
Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
March 28, 2024
Via
Chartmill
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024
From
Genmab A/S
Via
Business Wire
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
April 29, 2024
From
Pfizer Inc.
Via
Business Wire
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
April 25, 2024
Via
Investor's Business Daily
Analyst Ratings For Genmab
March 26, 2024
Via
Benzinga
4 Analysts Assess Genmab: What You Need To Know
February 20, 2024
Via
Benzinga
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
April 08, 2024
Via
Benzinga
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
April 06, 2024
Via
Talk Markets
Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio
April 03, 2024
Via
Investor's Business Daily
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
April 03, 2024
From
Genmab A/S
Via
Business Wire
NASDAQ:GMAB is showing good growth, while it is not too expensive.
March 21, 2024
Via
Chartmill
Why NASDAQ:GMAB Is a Promising High-Growth Stock in the Midst of Consolidation.
March 05, 2024
Via
Chartmill
NASDAQ:GMAB is showing good growth, while it is not too expensive.
February 29, 2024
Via
Chartmill
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
February 27, 2024
From
Genmab A/S
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.